Kidney function may change how hepatitis b drug works
NCT ID NCT07342881
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early study tests a single dose of the drug pevifoscorvir in 30 people with chronic hepatitis B, some with kidney problems and some with healthy kidneys. Researchers want to see how kidney function affects drug levels and safety. The goal is to learn how to dose the drug properly for patients with kidney impairment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pevifoscorvir sodium (ALG-000184)
- What this could lead to
- If successful, this study could help doctors decide the right dose of pevifoscorvir for people with kidney problems and chronic hepatitis B.
- What could go wrong
- This is a very early Phase 1 study with only 30 people. It looks at how the body processes the drug, not whether it works for hepatitis B. Results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Genesis Clinical Trials
RECRUITINGTampa, Florida, 33603, United States
-
Orlando Clinical Research Center
RECRUITINGOrlando, Florida, 32809, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.